Investigational Drug Information for FG-4592
✉ Email this page to a colleague
What is the development status for investigational drug FG-4592?
FG-4592 is an investigational drug.
There have been 28 clinical trials for FG-4592.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 20th 2022.
The most common disease conditions in clinical trials are Anemia, Renal Insufficiency, Chronic, and Kidney Diseases. The leading clinical trial sponsors are FibroGen, Astellas Pharma Europe B.V., and AstraZeneca.
There are forty-two US patents protecting this investigational drug and three hundred and seventy-seven international patents.
Summary for FG-4592
| US Patents | 42 |
| International Patents | 377 |
| US Patent Applications | 180 |
| WIPO Patent Applications | 122 |
| Japanese Patent Applications | 33 |
| Clinical Trial Progress | Phase 3 (2022-10-20) |
| Vendors | 91 |
Recent Clinical Trials for FG-4592
| Title | Sponsor | Phase |
|---|---|---|
| Evaluate the Efficacy and Safety of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis Patients | Second Xiangya Hospital of Central South University | Phase 4 |
| A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies | FibroGen | Phase 3 |
| Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD | AstraZeneca | Phase 3 |
Clinical Trial Summary for FG-4592
Top disease conditions for FG-4592
Top clinical trial sponsors for FG-4592
US Patents for FG-4592
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| FG-4592 | ⤷ Try a Trial | Nitrogen-containing heteroaryl compounds and methods of use thereof | FibroGen, Inc. (San Francisco, CA) | ⤷ Try a Trial |
| FG-4592 | ⤷ Try a Trial | Crystalline forms of a prolyl hydroxylase inhibitor | FibroGen, Inc. (San Francisco, CA) | ⤷ Try a Trial |
| FG-4592 | ⤷ Try a Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Try a Trial |
| FG-4592 | ⤷ Try a Trial | Generation of muscle lineage cells and therapeutic uses thereof | GENEA BIOCELLS USA (HOLDINGS), INC. (San Diego, CA) | ⤷ Try a Trial |
| FG-4592 | ⤷ Try a Trial | Crystalline forms of a prolyl hydroxylase inhibitor | FibroGen, Inc. (San Francisco, CA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for FG-4592
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| FG-4592 | Austria | AT496033 | 2023-06-06 | ⤷ Try a Trial |
| FG-4592 | Australia | AU2004245552 | 2023-06-06 | ⤷ Try a Trial |
| FG-4592 | Brazil | BRPI0411055 | 2023-06-06 | ⤷ Try a Trial |
| FG-4592 | Canada | CA2528232 | 2023-06-06 | ⤷ Try a Trial |
| FG-4592 | China | CN102718708 | 2023-06-06 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
